Advertisement

Sarcoidosis

  • Eleftherios Pelechas
  • Evripidis Kaltsonoudis
  • Paraskevi V. Voulgari
  • Alexandros A. Drosos
Chapter

Abstract

Sarcoidosis is a chronic, systemic inflammatory disorder characterised by the presence of epithelioid non-caseating granulomata in the affected organs. The lungs are affected in about 90% of the cases, and pulmonary disease accounts for most of the morbidity and mortality associated with sarcoidosis. Virtually every organ of the body can be affected like the liver, skin, eye etc. The features of granulomata are not specific for sarcoidosis and other conditions known to cause granulomata must be excluded. These conditions include mycobacterial and fungal infections, environmental agents such as beryllium, malignancy and others.

References and Further Reading

  1. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–55.Google Scholar
  2. Avasarala J. Infliximab in neurosarcoidosis. Neurology. 2017;89:2092–100.CrossRefGoogle Scholar
  3. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–9.CrossRefGoogle Scholar
  4. Bonifazi M, et al. Pulmonary Sarcoidosis. Semin Respir Crit Care Med. 2017;38(4):437–49.CrossRefGoogle Scholar
  5. Culver DA, et al. Neurosarcoidosis. Semin Respir Crit Care Med. 2017;38(4):499–513.CrossRefGoogle Scholar
  6. Drosos AA, Constantopoulos SH, Psychos D, et al. The forgotten cause of sicca complex. J Rheumatol. 1989;16(12):1548–51.PubMedGoogle Scholar
  7. Drosos AA, Voulgari PV, Psychos DN, et al. Sicca syndrome in patients with sarcoidosis. Rheumatol Int. 1999;18(5-6):177–80.CrossRefGoogle Scholar
  8. Joubert B, Chapelon-Abric C, Biard L, et al. Association of Prognostic Factors and Immunosuppressive Treatment with Long-term Outcomes in Neurosarcoidosis. JAMA Neurol. 2017;74(11):1336–44.CrossRefGoogle Scholar
  9. Psychos DN, Voulgari PV, Skopouli FN, Drosos AA, Moutsopoulos HM. Erythema nodosum: the underlying conditions. Clin Rheumatol. 2000;19(3):212–6.CrossRefGoogle Scholar
  10. Sayah DM, et al. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med. 2017;38(4):477–98.CrossRefGoogle Scholar
  11. West SG. Current Management of Sarcoidosis I: pulmonary, cardiac, and neurologic manifestations. Curr Opin Rheumatol. 2018;30(3):243–8.PubMedGoogle Scholar
  12. Yee AM. Sarcoidosis: rheumatology perspective. Best Pract Res Clin Rheumatol. 2016;30(2):334–56.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Eleftherios Pelechas
    • 1
  • Evripidis Kaltsonoudis
    • 1
  • Paraskevi V. Voulgari
    • 1
  • Alexandros A. Drosos
    • 1
  1. 1.Rheumatology Clinic - Department of Internal MedicineUniversity of IoanninaIoanninaGreece

Personalised recommendations